JP2020516673A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516673A5
JP2020516673A5 JP2019556314A JP2019556314A JP2020516673A5 JP 2020516673 A5 JP2020516673 A5 JP 2020516673A5 JP 2019556314 A JP2019556314 A JP 2019556314A JP 2019556314 A JP2019556314 A JP 2019556314A JP 2020516673 A5 JP2020516673 A5 JP 2020516673A5
Authority
JP
Japan
Prior art keywords
based hbv
protein
nucleic acid
hbv vaccine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556314A
Other languages
English (en)
Japanese (ja)
Other versions
JP7688480B2 (ja
JP2020516673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028116 external-priority patent/WO2018195165A1/en
Publication of JP2020516673A publication Critical patent/JP2020516673A/ja
Publication of JP2020516673A5 publication Critical patent/JP2020516673A5/ja
Priority to JP2023088820A priority Critical patent/JP2023123449A/ja
Application granted granted Critical
Publication of JP7688480B2 publication Critical patent/JP7688480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556314A 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法 Active JP7688480B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088820A JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762486618P 2017-04-18 2017-04-18
US62/486,618 2017-04-18
US201762553358P 2017-09-01 2017-09-01
US62/553,358 2017-09-01
US201862646978P 2018-03-23 2018-03-23
US62/646,978 2018-03-23
PCT/US2018/028116 WO2018195165A1 (en) 2017-04-18 2018-04-18 Methods for the treatment of subjects having a hepatitis b virus (hbv) infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088820A Division JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Publications (3)

Publication Number Publication Date
JP2020516673A JP2020516673A (ja) 2020-06-11
JP2020516673A5 true JP2020516673A5 (https=) 2021-05-27
JP7688480B2 JP7688480B2 (ja) 2025-06-04

Family

ID=71013269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556314A Active JP7688480B2 (ja) 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Country Status (1)

Country Link
JP (2) JP7688480B2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
CN118660708A (zh) * 2022-01-25 2024-09-17 公益财团法人川崎市产业振兴财团 用于经皮给药的含有rna的组合物和该组合物的给药方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
RS61118B1 (sr) 2016-01-12 2020-12-31 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Sredstva i postupci za lečenje hbv

Similar Documents

Publication Publication Date Title
US20170211068A1 (en) Immunostimulation by chemically modified rna
JP5087758B2 (ja) アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
EP2019857B1 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP1003531B1 (en) Processes for preparing nucleic acid constructs
ES2340499T3 (es) Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
AU2013308045B2 (en) Methods for the treatment of hepatitis B and hepatitis D infections
US6919319B2 (en) Immuno-modulating effects of chemokines in DNA vaccination
KR20110102424A (ko) 면역자극성 올리고뉴클레오타이드
US20250171507A1 (en) Cpg amphiphiles and uses thereof
JP2005508945A (ja) Ｃｐｇ配合物及び関連方法
BRPI0920240B1 (pt) composição adjuvante
RU2008102930A (ru) Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки
EA035967B1 (ru) Композиции для лечения гепатита в, содержащие олигонуклеотидные хелатные комплексы
JP2020516673A5 (https=)
KR100773390B1 (ko) 단순 포진 바이러스 백신 키트
CZ20014377A3 (cs) Koňský GM-CSF
JP2004533431A (ja) アジュバントとしてｉ型ｉｆｎを含むワクチン及びそれと関連する方法
Weeratna et al. Optimization strategies for DNA vaccines
US7384641B2 (en) Immuno-modulating effects of chemokines in DNA vaccination
EP4438047A1 (en) Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof
RU2823677C2 (ru) Cpg амфифилы и их применения
WO2022034555A1 (en) Polynucleotide constructs and uses thereof
Myers et al. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination
KR20220149519A (ko) B형 및 d형 간염의 치료 및 예방을 위한 조성물 및 방법
Madaan Heplisav V